CYCLO THERAPEUTICS, INC. Accounts Receivable, Credit Loss Expense (Reversal)
CYCLO THERAPEUTICS, INC. reported Accounts Receivable, Credit Loss Expense (Reversal) of $0 for the 12-month period ending 2023-12-31, per its 10-K/A filed 2024-12-18.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ProvisionForDoubtfulAccounts · last filed 2024-12-18
- CYCLO THERAPEUTICS, INC. accounts receivable, credit loss expense (reversal) for the quarter ending 2023-12-31 was $0.00, a 100.00% decline year-over-year.
- CYCLO THERAPEUTICS, INC. accounts receivable, credit loss expense (reversal) for the quarter ending 2022-12-31 was $32.03K, a 46.06% increase year-over-year.
- CYCLO THERAPEUTICS, INC. accounts receivable, credit loss expense (reversal) for the quarter ending 2021-12-31 was $21.93K.
- CYCLO THERAPEUTICS, INC. accounts receivable, credit loss expense (reversal) for the quarter ending 2021-09-30 was $0.00.
- CYCLO THERAPEUTICS, INC. accounts receivable, credit loss expense (reversal) for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- CYCLO THERAPEUTICS, INC. accounts receivable, credit loss expense (reversal) for fiscal 2022 was $10.27K, a 53.15% decline from fiscal 2021.
- CYCLO THERAPEUTICS, INC. accounts receivable, credit loss expense (reversal) for fiscal 2021 was $21.93K, a 1623.82% increase from fiscal 2020.
- CYCLO THERAPEUTICS, INC. accounts receivable, credit loss expense (reversal) for fiscal 2020 was $1.27K.
| Period end | Accounts Receivable, Credit Loss Expense (Reversal) 3 month | Accounts Receivable, Credit Loss Expense (Reversal) 6 month | Accounts Receivable, Credit Loss Expense (Reversal) 9 month | Accounts Receivable, Credit Loss Expense (Reversal) 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-12-18 | $0.00 10-K/A · filed 2024-12-18 | ||
| 2023-09-30 | $0.00 10-Q · filed 2023-11-14 | |||
| 2022-12-31 | $32.03K derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-12-18 | $10.27K 10-K/A · filed 2024-12-18 | ||
| 2022-09-30 | -$21.75K 10-Q · filed 2023-11-14 | |||
| 2021-12-31 | $21.93K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-17 | $21.93K derived: sum of 2 quarters · filed 2023-03-17 | $21.93K derived: sum of 3 quarters · filed 2023-03-17 | $21.93K 10-K · filed 2023-03-17 |
| 2021-09-30 | $0.00 10-Q · filed 2021-11-15 | $0.00 derived: sum of 2 quarters · filed 2021-11-15 | $0.00 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $0.00 10-Q · filed 2021-08-16 | $0.00 10-Q · filed 2021-08-16 | ||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | $0.00 derived: sum of 2 quarters · filed 2022-03-11 | $1.27K derived: sum of 3 quarters · filed 2022-03-11 | $1.27K 10-K · filed 2022-03-11 |
| 2020-09-30 | $0.00 10-Q · filed 2021-11-15 | $1.27K derived: sum of 2 quarters · filed 2021-11-15 | $1.27K 10-Q · filed 2021-11-15 | |
| 2020-06-30 | $1.27K 10-Q · filed 2021-08-16 | $1.27K 10-Q · filed 2021-08-16 | ||
| 2011-12-31 | -$6.00K 10-K · filed 2013-03-14 | |||
| 2010-12-31 | $6.00K 10-K · filed 2012-03-16 |